中文摘要：

本文研究了中药糖肾方对糖尿病肾病患者磷脂代谢的影响。采用正相HPLC-MS/TOF的方法进行血浆磷脂含量测定,观察糖尿病肾病Ⅲ期和Ⅳ期患者在给药前、给药3个月后和给药6个月后等不同阶段内血浆磷脂含量的变化,主要关注磷脂组学研究得到的潜在生物标记物。结果显示,与给药前相比,患者在常规西医治疗基础上服用糖肾方6个月后,PE750、PI885、PC792、PC826、PC830、PC854和PC802含量显著上升,LPC540含量下降,均趋于正常水平,但每个化合物的改善程度和起效时间不尽相同;在常规西医治疗基础上服用糖肾方的效果优于单独使用西医治疗组,其中糖尿病肾病Ⅳ期患者表现更为明显。实验结果表明,糖肾方对糖尿病肾病引起的体内磷脂代谢紊乱有一定的调节改善作用,可能与直接或间接抑制体内蛋白激酶C通路,降低磷脂酶A2活性有关;糖肾方可能用于治疗糖尿病肾病,至少可作为辅助治疗药物。

英文摘要：

This study was to report the effect of Tangshen Formula on phospholipids metabolism in diabetic nephropathy patients.A normal phase-HPLC-TOF/MS method was used in this study for the determination of seven species of phospholipids in human plasma.Then,the concentration changes of potential phospholipids biomarkers were discussed in diabetic nephropathy phase Ⅲ and phase Ⅳ patients among different groups,including before and 3,6 months after administration of Tangshen Formula.Significant increases of PE750,PI885,PC792,PC826,PC830,PC854 and PC802 levels were observed 6 months after administration of Tangshen Formula and conventional western medicine,as well as a decrease of LPC540 level,when compared with those before medication.Concentrations of all the potential phospholipids biomarkers showed a tendency towards normal levels;however,both the improvement degree and onset time of these compounds were not same.Additionally,Tangshen Formula treatment based on conventional western medicine treatment was more efficient in adjusting the levels of these compounds when compared with western medicine treatment alone,especially for the phase Ⅳ patients.These results indicated that Tangshen Formula was capable in regulating and improving phospholipids metabolism in diabetic nephropathy patients,which may be related with the direct or indirect inhibition of protein kinase C pathway and the corresponding reduction of phospholipase A2 activity.Therefore,Tangshen Formula may be used as an effective drug for diabetic nephropathy therapy,at least as an adjunctive therapeutic drug.